JP2022514465A5 - - Google Patents
Info
- Publication number
- JP2022514465A5 JP2022514465A5 JP2021531954A JP2021531954A JP2022514465A5 JP 2022514465 A5 JP2022514465 A5 JP 2022514465A5 JP 2021531954 A JP2021531954 A JP 2021531954A JP 2021531954 A JP2021531954 A JP 2021531954A JP 2022514465 A5 JP2022514465 A5 JP 2022514465A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- less
- lentiviral vector
- seq
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024192744A JP2025020288A (ja) | 2018-12-06 | 2024-11-01 | 第ｉｘ因子を発現するレンチウイルスベクターの使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862776393P | 2018-12-06 | 2018-12-06 | |
| US62/776,393 | 2018-12-06 | ||
| PCT/US2019/064711 WO2020118069A2 (en) | 2018-12-06 | 2019-12-05 | Use of lentiviral vectors expressing factor ix |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024192744A Division JP2025020288A (ja) | 2018-12-06 | 2024-11-01 | 第ｉｘ因子を発現するレンチウイルスベクターの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022514465A JP2022514465A (ja) | 2022-02-14 |
| JP2022514465A5 true JP2022514465A5 (https=) | 2022-11-16 |
| JP7644007B2 JP7644007B2 (ja) | 2025-03-11 |
Family
ID=69024682
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021531954A Active JP7644007B2 (ja) | 2018-12-06 | 2019-12-05 | 第ｉｘ因子を発現するレンチウイルスベクターの使用 |
| JP2024192744A Pending JP2025020288A (ja) | 2018-12-06 | 2024-11-01 | 第ｉｘ因子を発現するレンチウイルスベクターの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024192744A Pending JP2025020288A (ja) | 2018-12-06 | 2024-11-01 | 第ｉｘ因子を発現するレンチウイルスベクターの使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20200199626A1 (https=) |
| EP (1) | EP3891289A2 (https=) |
| JP (2) | JP7644007B2 (https=) |
| KR (1) | KR20210100661A (https=) |
| CN (1) | CN113396223A (https=) |
| AU (1) | AU2019393880A1 (https=) |
| BR (1) | BR112021010047A2 (https=) |
| CA (1) | CA3121786A1 (https=) |
| CO (1) | CO2021008877A2 (https=) |
| IL (1) | IL283547A (https=) |
| MX (2) | MX2021006648A (https=) |
| SG (1) | SG11202105880TA (https=) |
| TW (1) | TW202039855A (https=) |
| WO (1) | WO2020118069A2 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014127215A1 (en) | 2013-02-15 | 2014-08-21 | Biogen Idec Ma Inc. | Optimized factor viii gene |
| US11008561B2 (en) | 2014-06-30 | 2021-05-18 | Bioverativ Therapeutics Inc. | Optimized factor IX gene |
| CA3012695A1 (en) | 2016-02-01 | 2017-08-10 | Bioverativ Therapeutics Inc. | Optimized factor viii genes |
| KR20220097891A (ko) | 2019-09-30 | 2022-07-08 | 바이오버라티브 테라퓨틱스 인크. | 렌티바이러스 벡터 제형 |
| MX2023000156A (es) | 2020-06-24 | 2023-02-16 | Bioverativ Therapeutics Inc | Metodos para la eliminacion de factor viii libre de preparaciones de vectores lentivirales modificados para expresar dicha proteina. |
| TW202246505A (zh) * | 2021-03-05 | 2022-12-01 | 俄羅斯聯邦商亞那拜恩有限公司 | 編碼凝血因子ｉｘ蛋白的密碼子優化的核酸及其用途 |
| GB202205615D0 (en) * | 2022-04-14 | 2022-06-01 | Genespire S R L | Lentiviral vector |
| KR20250021306A (ko) * | 2022-04-14 | 2025-02-12 | 제네스파이어 에스.알.엘. | 렌티바이러스 벡터 |
| WO2025226943A1 (en) | 2024-04-25 | 2025-10-30 | Masonic Medical Research Laboratory | Polynucleotide for hepatocyte expression of vestigial like protein 4 and method of use thereof |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3045539B2 (ja) | 1989-02-21 | 2000-05-29 | ワシントン ユニバーシティ | 改変型生殖ホルモン |
| US6086875A (en) | 1995-01-17 | 2000-07-11 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of immunogens |
| US6485726B1 (en) | 1995-01-17 | 2002-11-26 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
| US6030613A (en) | 1995-01-17 | 2000-02-29 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| GB9621680D0 (en) | 1996-10-17 | 1996-12-11 | Oxford Biomedica Ltd | Lentiviral vectors |
| PT904392E (pt) | 1996-10-17 | 2001-06-29 | Oxford Biomedica Ltd | Vectores retrovirais |
| GB9622500D0 (en) | 1996-10-29 | 1997-01-08 | Oxford Biomedica Ltd | Therapeutic gene |
| US6207455B1 (en) | 1997-05-01 | 2001-03-27 | Lung-Ji Chang | Lentiviral vectors |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| EP2213743A1 (en) | 2000-04-12 | 2010-08-04 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| ATE437221T1 (de) | 2001-05-14 | 2009-08-15 | Gbp Ip Llc | Lentivirale vektoren kodierend für gerinnungsfaktoren für die gentherapie |
| AU2002364586A1 (en) | 2001-12-21 | 2003-07-30 | Delta Biotechnology Limited | Albumin fusion proteins |
| KR101271635B1 (ko) | 2001-12-21 | 2013-06-12 | 휴먼 게놈 사이언시즈, 인코포레이티드 | 알부민 융합 단백질 |
| US20080194481A1 (en) | 2001-12-21 | 2008-08-14 | Human Genome Sciences, Inc. | Albumin Fusion Proteins |
| JP2005526769A (ja) | 2002-03-15 | 2005-09-08 | ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド | 治療剤を全身搬送するための中央気道投与 |
| US6615782B1 (en) | 2002-04-12 | 2003-09-09 | Delphi Technologies, Inc. | Two-step finger follower rocker arm |
| ES2298745T3 (es) | 2003-04-24 | 2008-05-16 | Fondazione Centro San Raffaele Del Monte Tabor | Promotores bidireccionales de sintesis y utilizacion de los mismos. |
| EP1769078A1 (en) * | 2004-07-01 | 2007-04-04 | VIRxSYS Corporation | Vector packaging cell line |
| CA2609142C (en) | 2005-05-27 | 2016-02-09 | Fondazione Centro San Raffaele Del Monte Tabor | Therapeutic gene vectors comprising mirna target sequences |
| WO2007021494A2 (en) | 2005-08-12 | 2007-02-22 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US8048848B2 (en) | 2006-02-03 | 2011-11-01 | Prolor Biotech Ltd. | Long-acting interferons and derivatives thereof and methods thereof |
| GB0614780D0 (en) | 2006-07-25 | 2006-09-06 | Ucb Sa | Biological products |
| WO2008033413A2 (en) | 2006-09-14 | 2008-03-20 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| EP2144930A1 (en) | 2007-04-18 | 2010-01-20 | ZymoGenetics, Inc. | Single chain fc, methods of making and methods of treatment |
| EP2158318A2 (en) | 2007-05-14 | 2010-03-03 | Biogen Idec MA, Inc. | Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto |
| SI2173890T1 (sl) | 2007-06-21 | 2011-06-30 | Univ Muenchen Tech | Biološko aktivni proteini, ki imajo povečano in vivo in/ali in vitro stabilnost |
| EP2364362B1 (en) | 2008-11-12 | 2015-10-21 | Ospedale San Raffaele S.r.l. | Gene vector for inducing transgene-specific immune tolerance |
| ES2610356T3 (es) | 2009-02-03 | 2017-04-27 | Amunix Operating Inc. | Polipéptidos recombinantes extendidos y composiciones que comprenden los mismos |
| US8680050B2 (en) | 2009-02-03 | 2014-03-25 | Amunix Operating Inc. | Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same |
| US8703717B2 (en) | 2009-02-03 | 2014-04-22 | Amunix Operating Inc. | Growth hormone polypeptides and methods of making and using same |
| US9050269B2 (en) | 2009-03-10 | 2015-06-09 | The Trustees Of The University Of Pennsylvania | Protection of virus particles from phagocytosis by expression of CD47 |
| PL2424571T3 (pl) | 2009-04-30 | 2020-10-19 | Ospedale San Raffaele S.R.L | Wektor genowy |
| WO2010144508A1 (en) | 2009-06-08 | 2010-12-16 | Amunix Operating Inc. | Glucose-regulating polypeptides and methods of making and using same |
| KR101813727B1 (ko) | 2009-06-08 | 2018-01-02 | 아뮤닉스 오퍼레이팅 인코포레이티드 | 성장 호르몬 폴리펩타이드 및 이를 제조하고 사용하는 방법 |
| CA2771999A1 (en) | 2009-08-24 | 2011-03-10 | Amunix Operating Inc. | Coagulation factor vii compositions and methods of making and using same |
| WO2011028344A2 (en) | 2009-08-25 | 2011-03-10 | Amunix Operating Inc. | Interleukin-1 receptor antagonist compositions and methods of making and using same |
| SI2506868T1 (en) | 2009-12-06 | 2018-04-30 | Bioverativ Therapeutics Inc. | HYPER AND HYBRID POLYPETTIDES FACTOR VIII-FC AND METHODS FOR THEIR USE |
| EP3508573A1 (en) | 2010-07-09 | 2019-07-10 | Bioverativ Therapeutics Inc. | Systems for factor viii processing and methods thereof |
| TW201217527A (en) | 2010-07-09 | 2012-05-01 | Biogen Idec Hemophilia Inc | Processable single chain molecules and polypeptides made using same |
| CN104661674A (zh) | 2012-07-11 | 2015-05-27 | 阿穆尼克斯运营公司 | 具有xten和血管性血友病因子蛋白的因子viii复合物、及其用途 |
| TW202003554A (zh) | 2013-08-14 | 2020-01-16 | 美商百歐維拉提夫治療公司 | 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途 |
| US11008561B2 (en) * | 2014-06-30 | 2021-05-18 | Bioverativ Therapeutics Inc. | Optimized factor IX gene |
| EA201890423A1 (ru) | 2015-08-03 | 2018-07-31 | Биовератив Терапьютикс Инк. | Слитые белки фактора ix, способы их получения и применения |
| CA3012695A1 (en) * | 2016-02-01 | 2017-08-10 | Bioverativ Therapeutics Inc. | Optimized factor viii genes |
-
2019
- 2019-12-05 JP JP2021531954A patent/JP7644007B2/ja active Active
- 2019-12-05 KR KR1020217020427A patent/KR20210100661A/ko active Pending
- 2019-12-05 AU AU2019393880A patent/AU2019393880A1/en active Pending
- 2019-12-05 BR BR112021010047-4A patent/BR112021010047A2/pt unknown
- 2019-12-05 EP EP19828456.4A patent/EP3891289A2/en active Pending
- 2019-12-05 US US16/704,400 patent/US20200199626A1/en not_active Abandoned
- 2019-12-05 SG SG11202105880TA patent/SG11202105880TA/en unknown
- 2019-12-05 MX MX2021006648A patent/MX2021006648A/es unknown
- 2019-12-05 WO PCT/US2019/064711 patent/WO2020118069A2/en not_active Ceased
- 2019-12-05 CA CA3121786A patent/CA3121786A1/en active Pending
- 2019-12-05 TW TW108144569A patent/TW202039855A/zh unknown
- 2019-12-05 CN CN201980090827.7A patent/CN113396223A/zh active Pending
-
2021
- 2021-05-30 IL IL283547A patent/IL283547A/en unknown
- 2021-06-04 MX MX2025015374A patent/MX2025015374A/es unknown
- 2021-07-05 CO CONC2021/0008877A patent/CO2021008877A2/es unknown
-
2024
- 2024-11-01 JP JP2024192744A patent/JP2025020288A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022514465A5 (https=) | ||
| Di Pietro et al. | TRIM22 inhibits influenza A virus infection by targeting the viral nucleoprotein for degradation | |
| Busnadiego et al. | Host and viral determinants of Mx2 antiretroviral activity | |
| Das et al. | Interferon-inducible protein IFI35 negatively regulates RIG-I antiviral signaling and supports vesicular stomatitis virus replication | |
| JP2018502583A5 (https=) | ||
| Reynaud et al. | Human herpesvirus 6A infection in CD46 transgenic mice: viral persistence in the brain and increased production of proinflammatory chemokines via Toll-like receptor 9 | |
| Wilson et al. | Rhesus macaque TRIM5 alleles have divergent antiretroviral specificities | |
| Carthagena et al. | Implication of TRIMalpha and TRIMCyp in interferon-induced anti-retroviral restriction activities | |
| Lévy et al. | Lentiviral vectors displaying modified measles virus gp overcome pre-existing immunity in in vivo-like transduction of human T and B cells | |
| Sargiannidou et al. | Intraneural GJB 1 gene delivery improves nerve pathology in a model of X‐linked C harcot–M arie–T ooth disease | |
| Jáuregui et al. | Ovine TRIM5α can restrict visna/maedi virus | |
| Slough et al. | Two point mutations in old world hantavirus glycoproteins afford the generation of highly infectious recombinant vesicular stomatitis virus vectors | |
| JP2014523871A5 (https=) | ||
| Mamede et al. | Heterogeneous susceptibility of circulating SIV isolate capsids to HIV-interacting factors | |
| JP2019533434A5 (https=) | ||
| Badamchi-Zadeh et al. | Therapeutic efficacy of vectored PGT121 gene delivery in HIV-1-infected humanized mice | |
| AU2024278563A1 (en) | Means and methods for AAV gene therapy in humans | |
| Fuchs et al. | Tick-transmitted thogotovirus gains high virulence by a single MxA escape mutation in the viral nucleoprotein | |
| WO2014036524A4 (en) | Genetically modified msc and therapeutic methods | |
| JP2026000908A (ja) | 抗体に結合して中和抗体を阻害するための組成物および方法 | |
| Calame et al. | Retinal degeneration progression changes lentiviral vector cell targeting in the retina | |
| IL262459B1 (en) | Compositions and methods for enhanced gene expression of pklr for treatment of pyruvate kinase deficiency | |
| KR20230152008A (ko) | 단백질 m 유사체 및 융합 단백질 및 이들의 항체 기능 억제 용도 | |
| Janus et al. | Macaque antibodies targeting Marburg virus glycoprotein induced by multivalent immunization | |
| Li et al. | Stable HIV decoy receptor expression after in vivo HSC transduction in mice and NHPs: Safety and efficacy in protection from SHIV |